COVID Case series | OMI

This study aimed to investigate the clinical and biochemical characteristics of the COVID-19 patients and identify the biological markers and predictors of mortality among these patients. We have also assessed the therapeutic impact of different interventions in terms of disease severity amelioration and outcomes.

Data Collection: Data were collected using the electronic health records, from baseline (time of admission) to death or discharge. The patient's demographic details, baseline comorbidities, radiographic findings, laboratory findings, COVID-19 associated symptoms, inpatient treatment against COVID-19, disease progression, complications and outcomes were recorded.

Biochemical Assessments: Laboratory estimations, including CBC, creatinine, electrolytes, total bilirubin, ALT, AST, CPK, were assessed daily or every 2 to 3 days, based on the patient’s condition; CRP, D-dimer, ferritin, LDH, procalcitonin (PCT), Absolute Lymphocytic Count (ALC) & NLR were measured at baseline and at two days intervals. Pro-BNP was only measured among cases with suspected cardiac failure. Chest X-ray and ECG recordings were examined primarily on admission and then repeated as required depending on the abnormalities observed. HRCT scan was performed in all patients with dyspnea and SpO2 < 94% to monitor the radiological abnormalities. The scans were categorized as grade 1 for those with no chest X-ray findings, grade 2 where the chest X-ray had infiltrates involving < 50% of lung fields, grade 3 when the chest X-ray involved > 50% of lung fields, and grade 4 for those with bilateral opacities, not fully explained by volume overload, lobar or lung collapse, or nodules.